RESEARCH ARTICLE

Loss of Foxm1 Results in Reduced Somatotrope Cell Number during Mouse Embryogenesis

Michael J. Calderon1☯, Adam G. Ploegman1☯, Brock Bailey1, Deborah O. Jung1, Amy M. Navratil2, Buffy S. Ellsworth1*

1 Department of Physiology, Southern Illinois University, Carbondale, Illinois, United States of America, 2 Department of Zoology and Physiology, University of Wyoming, Laramie, Wyoming, United States of America

☯ These authors contributed equally to this work.
* bellsworth@siumed.edu

Abstract

FOXM1, a member of the forkhead box transcription factor family, plays a key role in cell cycling progression by regulating the expression of critical G1/S and G2/M phase transition genes. In vivo studies reveal that Foxm1 null mice have a 91% lethality rate at e18.5 due to significant cardiovascular and hepatic hypoplasia. Thus, FOXM1 has emerged as a key protein regulating mitotic division and cell proliferation necessary for embryogenesis. In the current study, we assess the requirement for Foxm1 in the developing pituitary gland. We find Foxm1 is expressed in the pituitary at embryonic days 10.5-18.5 and localizes with markers for active cell proliferation (BrdU). Interestingly, direct analysis of Foxm1 null mice at various embryonic ages, reveals no difference in gross pituitary morphology or cell proliferation. We do observe a downward trend in overall pituitary cell number and a small reduction in pituitary size in e18.5 embryos suggesting there may be subtle changes in pituitary proliferation not detected with our proliferation makers. Consistent with this, Foxm1 null mice have reductions in both the somatotrope and gonadotrope cell populations.

Introduction

The development of the anterior pituitary gland involves a highly orchestrated cascade of morphogenetic signals and transcription factors that give rise to five hormone-secreting cell lineages in a characteristic spatial and temporal manner. These endocrine cell lineages are of primary importance in the regulation of critical physiological functions including control of metabolism, growth, lactation, and reproduction. Despite recent progress defining the transcriptional mechanisms that underlie pituitary organogenesis and cell differentiation, our understanding of these mechanisms is far from complete. [1, 2].

Forkhead box (FOX) transcription factors are a family of proteins that share a highly conserved DNA binding domain [3] and control a range of functions in the cell, including
development [4, 5], cell cycle control [6, 7], cell survival [8–10], metabolism [11, 12], and immunoregulation [13, 14]. Interestingly, recent work has highlighted the observation that several forkhead factors affect both pituitary cell differentiation and function. The impact of forkhead proteins on pituitary development was made strikingly clear with the initial discovery that FOXL2 [15] regulates several genes necessary for gonadotrope function, including those that code for gonadotropin-releasing hormone receptor, Cga, and Fshb [16–20]. Indeed, without FOXL2, FSH production is severely impaired, causing infertility [21]. FOXP3, typically thought to be involved in the development and regulation of T cells, is not expressed in the pituitary gland, but is important for maintaining appropriate gonadotropin levels [22]. A mutation in Foxp3 results in severely reduced Lhb and Fshb levels, leading to infertility [22–24]. FOXD1, while also not expressed in the pituitary, appears essential for up regulation of genes necessary for LH production [25]. In contrast, FOXA1 is part of a complex that represses Gh1 expression [26]. Similarly, FOXO1 represses Lhb expression in studies using immortalized cell lines [27]. Thus, there is clear evidence that forkhead factors play a critical role in pituitary function. However, the role of the proliferation-associated forkhead transcription factor, FOXM1, within the pituitary remains largely undefined.

FOXM1 (Accession No. NM_008021) is a transcription factor that plays an essential role in organogenesis by controlling expression of genes involved in cell cycle progression and mitotic division. Given the critical role of cell proliferation in organ development, it is not surprising that deletion of Foxm1 results in 91% lethality by embryonic day (e)18.5 [28]. The high lethality can be attributed to significant cardiovascular anomalies including myocardium defects and ventricular hypoplasia [29]. In addition, hepatoblasts of the liver fail to enter mitosis [28], and severe abnormalities of pulmonary vasculature are also detected in Foxm1 null animals [30].

Previous work has found that FOXM1 is expressed in the embryonic pituitary [31]. Thus, we were intrigued with the possibility that FOXM1 plays an important role in cell proliferation necessary for pituitary development. Here we compare pituitary morphology, hormone production and cell proliferation of mouse embryos deficient in Foxm1 with their wild type littermates. We observe no difference in proliferation, but a reduction the number of somatotropes and gonadotropes is apparent.

Materials and Methods

Mice

Foxm1 knockout mice were graciously provided by Dr. Raychaudhuri, University of Illinois at Chicago, and maintained on a C57BL/6J background [28]. Mice were kept under a 12-hour dark-light cycle and fed Purina Mills FormulaLab diet 5008 ad libitum. The morning the copulatory plug was detected was considered to be embryonic day 0.5 (e0.5). Embryos were obtained from mating of Foxm1+/− mice. Littermates were used for all experiments in which normal and mutant embryos were compared. Genotyping for the wild type Foxm1 allele was performed using quantitative polymerase chain reaction (qPCR) with the following primers: 5′ − ATGTT GACACCAGGCTACCAGAA and 5′ − TATGTGTTGAACGCAGGAAGGTGA. To genotype the null allele, polymerase chain reaction (PCR) was used with the following primers: 5′ − TGGCT TCCACAGCTACAAATC and 5′ − TCTCCTCAATTCAAGACCAG.

The Southern Illinois University Animal Care and Use Committee approved all procedures using mice (Animal Assurance Number A-3078-01). All experiments were conducted in accord with the principles and procedures outlined in the NIH Guidelines for the Care and Use of Experimental Animals.
Histology and Immunohistochemistry

To detect cell proliferation in embryonic pituitaries, pregnant mice were given an intraperitoneal injection of bromodeoxyuridine (BrdU) at 100 μg/g body weight 2 hours before the embryos were collected [32]. Pregnant dams were euthanized by CO2 inhalation and embryos were dissected from the uterus. Embryos were euthanized by submerging in ice cold PBS.

Embryos were fixed in 4% formaldehyde in phosphate buffered saline (PBS; pH 7.2) for 45 minutes to 24 hours (depending on the stage of development). Any embryos that were discolored or underdeveloped as compared to littermates were considered dead and were not included in our analyses. All samples were then washed in PBS, dehydrated in a graded series of ethanol and embedded in paraffin. Five micron sections were deparaffinized in xylene, rehydrated through a series of graded ethanol washes. Mid-coronal sections that were comparable between wild type and mutants were chosen for immunohistochemistry to label the various hormone-secreting cell types at e17.5 and e18.5. Due to the small size of early stage pituitaries, mid-sagittal, rather than coronal, sections were chosen for pituitary stages prior to e17.5.

To visualize BrdU, FOXM1 and phosphohistone H3 (pHH3), endogenous peroxidases were removed with 1.5% hydrogen peroxide in water. Epitopes were then unmasked by boiling in 10mM citric acid for 10 minutes followed by a 20 minute cool down. The specimens were blocked using the blocking solution from the tyramide signal amplification (TSA) fluorescein isothiocyanate (FITC) kit (Perkin-Elmer Life Sciences, Boston, MA) for 10 minutes then incubated with primary antibodies for BrdU (Invitrogen, Boston, MA, mouse, 1:100), FOXM1 (Santa Cruz Biotechnology, Santa Cruz, CA, rabbit, 1:30) or pHH3 (Millipore, Temecula, CA, rabbit, 1:100) overnight at 4°C (Table 1). BrdU specimens were then incubated with the appropriate anti-mouse biotinylated secondary antibodies (Vector, Burlingame, CA, goat, 1:200) for 30 minutes while FOXM1 and pHH3 specimens were incubated with biotinylated anti-rabbit antibodies (Jackson, West Grove, PA, goat, 1:200). All specimens were incubated in streptavidin-horseradish peroxidase (Perkin-Elmer) for 30 minutes, followed by a 10 minute incubation in FITC (Perkin-Elmer). The sections were finally incubated for 5 minutes with 4',6-diamidino-2-phenylindole (DAPI) (1:100; 167 nM, Molecular Probes, www.invitrogen.com) and mounted using Aquamount (Lerner Laboratories, Pittsburgh, PA).

Table 1. Antibody Information.

| Name          | Clonality | Host       | Supplier          | Cat. No. | Immunogen                        | Registry ID   |
|---------------|-----------|------------|-------------------|----------|----------------------------------|---------------|
| FOXM1         | polyclonal| rabbit     | Santa Cruz        | sc-502   | C-terminus of human FOXM1        | AB_631523     |
| BrdU          | monoclonal| mouse      | Life Technologies | B35128   | 5-iodouridine                    | AB_10562901   |
| p57           | polyclonal| rabbit     | Santa Cruz        | sc-8298  | aa 45–135 of human p57           | AB_2078155    |
| pH3           | polyclonal| rabbit     | Millipore         | 06–570   | human pH3 (Ser10)                | AB_310177     |
| pERK          | monoclonal| rabbit     | Cell Signaling    | 4370     | Thr202/Tyr204 of human p44 MAP kinase | AB_2315112    |
| ACTH          | polyclonal| rabbit     | NHPP               | N/A      | rat ACTH                         | AB_2313902    |
| TSHB          | polyclonal| rabbit     | NHPP               | N/A      | rat TSHB                         | N/A           |
| GH            | polyclonal| rabbit     | NHPP               | N/A      | mouse GH                         | N/A           |
| CGA           | polyclonal| rabbit     | NHPP               | N/A      | rat CGA                          | N/A           |
| LHB           | polyclonal| guinea pig | NHPP               | N/A      | rat LHB                          | N/A           |
| biotin anti-mouse | polyclonal| goat       | Vector Laboratories| BA-9200 | mouse                            | AB_2336171    |
| biotin anti-rabbit | polyclonal| goat       | Jackson Laboratories| 111–067–003  | rabbit                          | AB_2337971    |
| alexa fluor 488 anti-rabbit | polyclonal| goat       | Molecular Probes | A-11008 | rabbit                          | AB_143165     |
| TRITC-anti-guinea pig | polyclonal| donkey | Jackson Laboratories | 706–026–148 | guinea pig                       | AB_2340446    |
| TRITC-anti-rabbit | polyclonal| goat       | Jackson Laboratories | 111–297–003 | rabbit                          | AB_2338034    |

doi:10.1371/journal.pone.0128942.t001
Double immunohistochemistry for FOXM1 with BrdU or pHH3, was performed by detecting FOXM1 as described above. Tissue sections were then blocked for 15 minute with streptavidin and biotin block (Vector Laboratories, 1:50) as well as with anti-rabbit Fab fragment according to manufacturer’s instructions and BrdU or pHH3 was detected as described above, except that sections were incubated with TRITC (Perkin-Elmer) rather than FITC. Controls in which each primary antibody was omitted were performed and revealed minimal cross-reactivity between stains (data not shown).

For immunofluorescent labeling of p-ERK1/2, pituitary sections were fixed, embedded, and epitopes unmasked as described above. Sections were washed in TBS and blocked with 10% normal goat serum/2x casein in TBS for 30 min at room temperature. Sections were then incubated in anti-p-ERK1/2 primary antibody diluted 1:80 in TBS/1× casein overnight; additionally normal rabbit IgG at equivalent concentration (micrograms/ml) was used as negative control. After overnight primary antibody incubation, sections were washed with TBS and incubated with Alexa Fluor 488 anti-rabbit secondary antibody (1:100) for 20 min at room temperature in the dark. Slides were then washed and mounted in Vectashield with DAPI. Images were obtained on a Zeiss 710 Laser Scanning Confocal Microscope using the appropriate filters.

To visualize adrenocorticotropic hormone (ACTH), thyroid stimulating hormone (TSHB), growth hormone (GH), the common α-subunit (CGA) and luteinizing hormone (LHB), tissue sections were blocked with TSA blocking solution (Perkin-Elmer Life Sciences) and incubated with the appropriate antibody (National Hormone and Peptide Program, Torrance, CA) for one hour at room temperature. Tissue sections were incubated with anti-guinea pig or anti-rabbit secondary antibodies that are directly conjugated to TRITC (Jackson Immunoresearch West Grove, PA, 1:100) for 30 minutes to detect LHB or ACTH, GH, TSHB and CGA, respectively. Sections were stained with DAPI and mounted as above.

Pituitary morphology was observed by staining tissue sections with hematoxylin and eosin. Briefly, paraffin was melted and then removed with two washes of citraclear. The sections were then washed in three changes of 100% ethanol for two minutes each, wash in distilled water for two minutes, incubated in filtered hematoxylin for 4 minutes then washed in distilled water. Sections were dipped in acid alcohol and then lithium carbonate followed by a rinse in distilled water and then dipped in eosin 1–5 times. Sections were placed in 100% isopropyl alcohol three times for 2 minutes each before mounting.

Digital images were captured with a Leica DM 5000B fluorescent microscope and Retiga 2000R digital camera. DAPI and the corresponding FITC and/or TRITC pictures were merged using Adobe Photoshop CS3.

Histological Quantification

Phosphohistone H3-positive cells were separated into dimly fluorescent cells, which mark cells in late G2 phase, and brightly stained cells, which mark cells in M phase [33]. The total number of pituitary cells was counted by labeling cell nuclei with DAPI. A ratio of cells in late G2 or in M phase to total DAPI count was calculated for each pituitary. Four to five littermate pairs were analyzed and one section was counted per pituitary.

The total number of BrdU-positive and DAPI-positive cells per tissue section were counted at ages e10.5, e12.5 and e14.5. The entire pituitary could be viewed at 200x magnification at all ages. A ratio of positive cells to total DAPI count was calculated for each pituitary. Four to five littermate pairs were analyzed and one section was counted per pituitary.

LHB, GH, TSHB, CGA and ACTH-positive cells and DAPI-positive cells were counted manually at e17.5 and e18.5. The entire pituitary could not be viewed at 200x magnification, so only half of the pituitary was counted. Only the intermediate and anterior lobes were counted.
A ratio of positive cells to total DAPI count was calculated for each pituitary. The ratios were then standardized to the wild type littermate. Four to seven littermate pairs were analyzed and one section was counted per pituitary.

Area was determined for approximately three sections per pituitary using ImageJ64. The anterior pituitary was outlined in ImageJ64 and area was measured in μm². Values were set relative to wild type controls for each littermate pair. Four littermate pairs were analyzed for the e12.5 age group and eight littermate pairs were analyzed for the e14.5 and e18.5 age groups.

### Quantitative RT-PCR

Pituitary glands were dissected from e17.5 and e18.5 embryos. RNA was then isolated using the RNAqueous-Micro kit (Ambion, Inc.) according to manufacturer’s instructions. RNA was treated with DNase I and DNase inactivating reagent from the TURBO DNase-free kit (Ambion, Inc.) as per manufacturer’s instructions. RNA concentrations were determined by spectrophotometry at 260nm. Ten ng of total RNA was used with the TaqMan RNA-to-CT 1-step Kit and TaqMan probes. Amplification was accomplished using Taqman Gene Expression Assays (Applied Biosystems) as per manufacturer’s instructions: Cga (Accession No. NM_009889)(Mm01209400_m1), Ghl (Accession No. NM_008117)(Mm00433590_g1), Pomc (NM_001278581)(Mm00435874_m1), Lhb (Accession No. NM_008497)(Mm00656868_g1) and Tshb (Accession No. (Accession No. BC144732)(Mm00437190_m1), utilizing Actb (Accession No. NM_007393)(4352933E) as the endogenous control (all Taqman probes from Applied Biosystems, Inc.). All experiments were performed in triplicate. Real time RT-PCR was performed on a CFX96 Real Time System (BioRad). Experiments were run at 48°C for 15 minutes to synthesize the cDNA followed by 10 minutes at 95°C to deactivate the reverse transcriptase and activate the Taq polymerase and then 40 cycles of 95°C for 15 seconds and 60°C for 1 minute for amplification. No-template controls and no-reverse transcriptase controls were used to assure the absence of contamination and efficacy of the DNase treatment, respectively. Melt curve analysis was performed to ensure that no primer-dimer amplification occurred. Data were analyzed by the ΔΔCT method [34, 35]. The values for ΔΔCT were calculated by subtracting the average ΔCT of wild type controls from the ΔCT for each sample. CT values over 30 were considered unreliable and were not included in our analyses.

### Statistical Analysis

All results are expressed as mean ± SEM. Data were analyzed by Student’s t-test using Microsoft Excel. P-values less than 0.05 were considered significant (*).

### Results

**FOXM1 Expression During Pituitary Development**

To begin identifying the role that FOXM1 plays in anterior pituitary organogenesis, we first examined the spatial and temporal distribution of FOXM1 in the normal mouse pituitary over the course of embryonic development and in adulthood using immunohistochemistry. While FOXM1 was present at all ages examined, the proportion of FOXM1 immuno-positive nuclei dropped as development progressed. At early embryonic ages (Fig 1A and 1B), a large percentage of the cells in the nascent pituitary contain the FOXM1 protein, consistent with high levels of cell proliferation at these stages of development. With the beginning of terminal differentiation in the pituitary, a reduction in FOXM1 positive cells was seen at e14.5 (Fig 1C–1F)[1, 36, 37]. To directly test whether FOXM1 localizes to proliferating cells, we performed double immunohistochemistry on wild type mice at e16.5, for FOXM1 and BrdU.
We found that within the pituitary, FOXM1 consistently co-localizes with BrdU. Non-cycling precursors were marked by labeling p57 [38]. We found that FOXM1 is not present in cells that have left the cell cycle, consistent with its role as a promoter of cell cycle progression (Fig 2D–2F).

Pituitary Morphology and Cell Proliferation in Foxm1-Deficient Embryos

Our data support the conclusion that FOXM1 is present in actively dividing pituitary cells during early stages of development, thus we hypothesized that deletion of Foxm1 would lead to significant malformation of Rathke’s pouch. If correct, we would expect changes in gross pituitary...
morphology. To test this notion, we compared wild type embryos stained with hematoxylin and eosin with their Foxm1 null littermates (Fig 3). Surprisingly, morphological analysis did not reveal any overt changes in overall pituitary structure.

Despite no change in morphology, at issue is the level of cell proliferation within pituitary from Foxm1 null embryos. To directly test this, proliferation of Foxm1 null embryos and their wild type littermates was compared using pHH3. Not only is pHH3 a proliferation marker, it can also be used to differentiate between cells in late G2 phase and M phase. G2 cells have significantly fewer histones phosphorylated and so stain more dimly than cell in M phase, which are brightly stained due to the increased phosphorylated H3 subunits [33]. When Foxm1 null embryos were compared to their wild type littermates, there was no statistical difference in the number of G2 phase cells, M phase cells or total pHH3 positive cells at e10.5, e12.5 or e14.5 (Fig 4A–4L). Extracellular signal regulated kinase (ERK), promotes proliferation in many tissues and its activity is sustained by FOXM1 in hepatocellular carcinoma cells [39, 40]. Consistent with no changes in pituitary cell proliferation, we also observed no difference in activity of ERK in Foxm1 null embryos at e10.5 (data not shown).

As an alternative proliferation marker, BrdU was also analyzed. Again, no significant difference in the number of BrdU-positive cells in the pituitary gland was observed between Foxm1 null embryos and wild type littermates at e10.5, e12.5 or e14.5 (Fig 5A–5I). In agreement with the literature, the percent of cells staining for BrdU in the pituitary fell with increasing age (data not shown). Additionally, pituitary sections from wild type and Foxm1 null embryos were labeled with the proliferation marker, Ki67. No significant difference in the number of Ki67-immunopositive cells was observed between genotypes (data not shown).

Our data suggests there are no changes in anterior pituitary cell proliferation and morphology in Foxm1 null embryos, therefore we next sought to confirm our results by quantitatively analyzing the pituitary cell density. Pituitary sections were labeled with DAPI and stained cells

Fig 2. FOXM1 is present in actively proliferating cells. FOXM1 (green) and a marker for cells in S phase, BrdU (red), were labeled in midsagittal pituitary sections from wild type e16.5 mouse embryos (A-C). FOXM1 (green) and a marker for non-cycling precursors, p57 (red), were labeled in midsagittal pituitary sections from wild type e14.5 mouse embryos (D-F). Scale bar represents 100 μm.

doi:10.1371/journal.pone.0128942.g002
Fig 3. *Foxm1*<sup>−/−</sup> pituitary glands exhibit normal morphology. Pituitary glands of *Foxm1*<sup>−/−</sup> embryos (KO) and wild type littermates (WT) were stained with hematoxylin and eosin at (A-B) embryonic day 10.5 (e10.5), (C-D) e12.5, (E-F) e14.5 and (G-H) e18.5. No gross morphological differences were seen between the pairs. Scale bar represents 100 µm.

doi:10.1371/journal.pone.0128942.g003
were quantitated. We observed no significant difference between the number of cells per pituitary section between Foxm1 null embryos and their wild type littermates at e10.5, e12.5, e14.5 and e18.5, although there was a trend toward decreased cell number in Foxm1 null pituitary glands at later ages (Fig 5).
Fig 5. No significant difference in S phase is apparent in Foxm1<sup>−/−</sup> pituitary glands. (A-F) BrdU (red) was used as a marker for cells in S phase and DAPI (blue) labels all cell nuclei. Scale bar represents 100 μm. (G-I) A ratio of BrdU-positive cells to total DAPI count per pituitary section was calculated for Foxm<sup>−/−</sup> embryos (KO) and wild type littermates (WT) at each age. Data are expressed as mean ± SEM of four or five littermate pairs for each age. The data were analyzed by Student t-test to determine significant difference between WT and KO. (J) The total number of cells per pituitary section was counted for embryonic day 10.5 (e10.5), e12.5, e14.5, e18.5 in Foxm<sup>−/−</sup> (KO) and wild type littermates (WT). Data are expressed as mean ± SEM of six littermate pairs for each age. The data were analyzed by Student t-test to determine significant difference between WT and KO. (K) Area of approximately three pituitary sections per individual was measured. Values are shown relative to WT littermate controls. Data are expressed as mean ± SEM of four littermate pairs for e12.5 and eight littermate pairs for e14.5 and e18.5. The data were analyzed by Student t-test to determine significant difference between WT and KO (*)P<0.05.

doi:10.1371/journal.pone.0128942.g005
To more carefully analyze pituitary size, the area of pituitary tissue sections was measured at e12.5, e14.5 and e18.5 (Fig 5K). Foxm1 null embryos were not significantly smaller at e12.5 or e14.5, although there was a downward trend in area of pituitary sections at e14.5. At e18.5 there was a small but significantly decrease in area of pituitary sections in Foxm1 null embryos as compared to wild type littermate controls, suggesting that Foxm1 is required for normal growth of the embryonic pituitary gland.

**Hormone Production in Foxm1-Deficient Embryos**

To determine if Foxm1 is required for normal pituitary cell lineage commitments, immunohistochemistry was performed on e17.5-e18.5 embryos deficient in Foxm1 or their wild type littermates for markers of the 5 endocrine cell types. Individual cell types from Foxm1 null embryos and wild type littermates were counted and expressed as a ratio of the total number of pituitary cells (Fig 6A–6O). Interestingly, the number of GH-, CGA- and LHB-positive cells was significantly reduced in Foxm1 null embryos, suggesting that Foxm1 is required for normal numbers of somatotropes and gonadotropes to differentiate. No significant difference was observed in the number of ACTH- or TSHB-positive cells.

To more accurately quantify hormone expression in Foxm1 null embryos, we employed quantitative reverse transcription polymerase chain reaction (qRT-PCR). Consistent with a reduced number of somatotropes, expression of the gene encoding for GH (Gh1) was modestly but significantly reduced in Foxm1 null embryos as compared to wild type littermates (Fig 7). While expression of Lhb and Cga showed a trend toward being reduced in Foxm1 null embryos, this was not statistically significant. While not statistically significant, an upward trend was observed in expression of Pomc or Tshb. We did not assess prolactin or follicle-stimulating hormone mRNA levels because they are present in such low quantities in the embryo it is very difficult to measure reliably [41].

**Discussion**

Previous work has highlighted the essential role of FOXM1 in cell cycle progression in various tissues [28, 42] although its role in pituitary organogenesis remains unknown. We find that FOXM1 is present in actively proliferating pituitary cells during development consistent with a role in promoting proliferation during pituitary development (Fig 1). Interestingly, when we assessed the number of proliferating cells in in the pituitary glands of Foxm1 null embryos, we saw no statistical difference in proliferation at any age analyzed (Figs 4 and 5). However, we did observe a downward trend in the number of cells at e18.5 (Fig 5J). Additionally, the area of Foxm1−/− pituitaries is significantly reduced at e18.5 (Fig 5K). These data, together with the fact that we observe a decrease in the number of somatotropes and gonadotropes, (Figs 6 and 7) suggest there may be a subtle defect in pituitary cell proliferation in Foxm1 null embryos that is not statistically significant. If correct, it would suggest a differential requirement of FOXM1 for proliferation among precursors for the various pituitary hormone-producing cells. This is not without precedent; in pulmonary tissues. Kim, et al. [30] observed a reduction in proliferation of the embryonic Foxm1 null lung mesenchyme, however proliferation was normal in Foxm1 null epithelial cells.

During anterior pituitary development, corticotropes arise first, followed by thyrotropes. Somatotropes, gonadotropes and lactotropes terminally differentiate later [43]. We did not assess lactotrope differentiation because prolactin is present in such low levels in the embryo it is very difficult to measure reliably [41]. The fact that corticotropes and thyrotropes exhibit an upward trend, although statistically insignificant, while somatotropes and gonadotropes are reduced in the absence of Foxm1 null mice suggests a temporal requirement for FOXM1 during
Fig 6. The number of cells containing GH, LHB, and CGA are reduced in Foxm1\(^{-/-}\) pituitary glands. Immunohistochemistry for (A-B) GH (red), (D-E) CGA (red), (G-H) ACTH (red), (J-K) LHB (red), (M-N) TSHB (red) was performed on e17.5/18.5 coronal sections. DAPI (blue) labels all cell nuclei. Scalebar represents 100 \(\mu\)m. The total number of cells containing (C) GH, (F) CGA, (I) ACTH, (L) LHB, (O) TSHB and total DAPI in each pituitary were counted for Foxm1\(^{-/-}\) embryos (KO) and wild type (WT) littermates. The KO ratio (hormone/DAPI) was then normalized to the WT ratio. Data are expressed as mean \(\pm\) SEM of 4–6 littermate pairs for each age. The data were analyzed by Student t-test to determine significant difference between WT and KO (*P < 0.05).

doi:10.1371/journal.pone.0128942.g006
pituitary development, and a possible shift in the pituitary cell population toward the cells that differentiate early in pituitary ontogeny, namely the corticotropes and thyrotropes and away from cells that differentiate later, somatotropes and gonadotropes. It is unlikely that these small changes in hormone expression would affect embryonic development or growth and fertility of these mice had they been able to live to adulthood.

Lineage commitment and differentiation of cells occur in a sequential manner and are orchestrated by combinatorial expression of cell type-specific transcription factors and epigenetic modifications. Thus, it is possible that FOXM1 contributes to differentiation of hormone-secreting cell types in the developing pituitary gland rather than or in addition to their proliferation. Towards this end, recent work has highlighted that FOXM1 facilitates the differentiation of bronchiolar epithelial cells in mice and primary neuronal differentiation in *Xenopus* [44]. The reduction in somatotropes and gonadotropes that we observe in *Foxm1*−/− embryos could be due to misregulation of transcription networks that are involved in the differentiation of these cell types in the absence of FOXM1. It is known that *Foxm1* is required for β-catenin activation and the expression of Wnt target genes [45]. β-catenin has recently been shown to play a critical role in a multicomponent transcriptional network required for regulated expression of *Cga* and *Lhb* in the gonadotrope [46]. In somatotropes, β-catenin is important in maintaining homotypic cell to cell contacts. Reduction of β-catenin correlates with disruption in the organization of the somatotrope cell network [47]. The inability of somatotropes to effectively communicate with one another and initiate coordinated and appropriate signal transduction could contribute to reduced GH expression seen in our model.

We conclude that FOXM1 is required for normal somatotrope and gonadotrope numbers and for normal pituitary size. The reduction in cell numbers and pituitary size may be due to effects on proliferation of pituitary precursor cells that are too subtle to be detected using our current methodology. Alternatively, the reduction in the number of somatotrope and gonadotrope cells could indicate a role for FOXM1 in differentiation of these cell types. The effects of FOXM1 on pituitary cell number and/or differentiation may be partially compensated for by

**Fig 7. Expression of *Gh1* is reduced in *Foxm1*−/− pituitary glands.** Real time RT-PCR for the genes encoding growth hormone (*Gh1*), luteinizing hormone β (*Lhb*), the common α subunit (*Cga*), the precursor for ACTH (*Pomc*) and thyroid stimulating hormone (*Tshb*) was performed on RNA isolated from pituitary of e17.5 and e18.5 *Foxm1*−/− embryos (KO) and wild type littermates (WT). Values were calculated using the ΔΔCT method and normalized to WT. Data are expressed as mean ± SEM of 7 littermate pairs for each age and were analyzed by Student t-test to determine significant difference between WT and KO (*P < 0.05).

![Graph](image-url)

**Fig 7.** Expression of *Gh1* is reduced in *Foxm1*−/− pituitary glands. Real time RT-PCR for the genes encoding growth hormone (*Gh1*), luteinizing hormone β (*Lhb*), the common α subunit (*Cga*), the precursor for ACTH (*Pomc*) and thyroid stimulating hormone (*Tshb*) was performed on RNA isolated from pituitary of e17.5 and e18.5 *Foxm1*−/− embryos (KO) and wild type littermates (WT). Values were calculated using the ΔΔCT method and normalized to WT. Data are expressed as mean ± SEM of 7 littermate pairs for each age and were analyzed by Student t-test to determine significant difference between WT and KO (*P < 0.05).
other factors and is a focus of our ongoing work. Identification of these factors in the future will help elucidate the comprehensive role of FOXM1 in pituitary development.

Acknowledgments

We thank Pradip Raychaudhuri, University of Illinois Chicago, for providing us with Foxm1 heterozygous null mice originally developed by the late Robert Costa. We thank A.F. Parlow and the National Hormone and Pituitary Program, the National Institute of Diabetes and Digestive and Kidney Diseases, and the National Institute of Child Health and Human Development for providing antibodies for TSHB, GH, LHB, ACTH and CGA. We thank Maureen Doran for her guidance in our histological studies.

Author Contributions

Conceived and designed the experiments: MJC AGP BB DOJ AMN BSE. Performed the experiments: MJC AGP BB DOJ AMN BSE. Analyzed the data: MJC AGP BB DOJ AMN BSE. Contributed reagents/materials/analysis tools: AMN BSE. Wrote the paper: MJC AGP BB DOJ AMN BSE.

References

1. Davis SW, Castinetti F, Carvalho LR, Ellsworth BS, Potok MA, Lyons RH, et al. Molecular mechanisms of pituitary organogenesis: In search of novel regulatory genes. Mol Cell Endocrinol. 2010; 323(1):4–19. Epub 2009/12/23. S0303-7207(09)00620-0 [pii] doi: 10.1016/j.mce.2009.12.012 PMID: 20025935.
2. Cheung CC, Lustig RH. Pituitary development and physiology. Pituitary. 2007; 10(4):335–50. Epub 2007/07/20. doi: 10.1007/s11102-007-0051-9 PMID: 17638086.
3. Wijchers PJ, Burbach JP, Smidt MP. In control of biology: of mice, men and Foxes. Biochem J. 2006; 397(2):233–46. PMID: 16792526.
4. Nishimura DY, Searby CC, Alward WL, Walton D, Craig JE, Mackey DA, et al. A spectrum of FOXC1 mutations suggests gene dosage as a mechanism for developmental defects of the anterior chamber of the eye. Am J Hum Genet. 2001; 68(2):364–72. PMID:11170889.
5. Mirzayans F, Gould DB, Heon E, Billingsley GD, Cheung JC, Mears AJ, et al. Axenfeld-Rieger syndrome resulting from mutation from the FKH7 gene on chromosome 6p25. Eur J Hum Genet. 2000; 8(1):71–4. Epub 2000/03/14. doi: 10.1038/sj.ejhg.5200354 PMID: 10719890.
6. Medema RH, Kops GJ, Bos JL, Burgering BM. AFX-like Forkhead transcription factors mediate cell-cycle regulation by Ras and PKB through p27Kip1. Nature. 2000; 404(6779):782–7. PMID:1073894.
7. Martinez-Gac L, Marques M, Garcia Z, Campanero MR, Carrera AC. Control of cyclin G2 mRNA expression by forkhead transcription factors: novel mechanism for cell cycle control by phosphoinositide 3-kinase and forkhead. Mol Cell Biol. 2004; 24(5):2181–9. Epub 2004/02/18. PMID:14966295.
8. Brunet A, Bonni A, Zigmond MJ, Lin MZ, Juo P, Hu LS, et al. Akt Promotes Cell Survival by Phosphorylating and Inhibiting a Forkhead Transcription Factor. Cell. 1999; 96(6):857–68. PMID:10102273
9. Nakamura N, Ramaswamy S, Vazquez F, Signoretti S, Loda M, Sellers WR. Forkhead transcription factors are critical effectors of cell death and cell cycle arrest downstream of PTEN. Mol Cell Biol. 2000; 20(23):8968–82. Epub 2000/11/14. PMID: 11073996.
10. Kops GJ, Medema RH, Glassford J, Essers MA, Dijkers PF, Coffer PJ, et al. Control of cell cycle exit and entry by protein kinase B-regulated forkhead transcription factors. Mol Cell Biol. 2002; 22(7):2025–36. Epub 2002/03/09. PMID:11845991.
11. Shih DQ, Navas MA, Kuwajima S, Duncan SA, Stoffel M. Impaired glucose homeostasis and neonatal mortality in hepatocyte nuclear factor 3alpha-deficient mice. Proc Natl Acad Sci U S A. 1999; 96(18):10152–7. Epub 1999/09/01. PMID: 10468578.
12. Shen W, Scearce LM, Brestelli JE, Sund NJ, Kaestner KH. Foxa3 (hepatocyte nuclear factor 3gamma) is required for the regulation of hepatic GLUT2 expression and the maintenance of glucose homeostasis during a prolonged fast. J Biol Chem. 2001; 276(46):42812–7. Epub 2001/09/08. doi: 10.1074/jbc.M1063442000.M1063442000 [pii]. PMID:11546810.
13. Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science, 2003; 299(5609):1057–61. Epub 2003/01/11. doi: 10.1126/science.1079490 1079490

PLOS ONE | DOI:10.1371/journal.pone.0128942 June 15, 2015 14 / 16
14. Nehls M, Pfeifer D, Schorpp M, Hedrich H, Boehm T. New member of the winged-helix protein family disrupted in mouse and rat nude mutations. Nature. 1994; 372(6501):103–7. Epub 1994/11/03. doi: 10.1038/372103a0 PMID: 7969402.

15. Treier M, Gleiberman AS, O’Connell SM, Szeto DP, McMahon JA, McMahon AP, et al. Multistep signaling requirements for pituitary organogenesis in vivo. Genes Dev. 1998; 12(11):1691–704. PMID: 9620855.

16. Ellsworth BS, Egashira N, Haller JL, Butts DL, Cocquet J, Clay CM, et al. FOXL2 in the pituitary: molecular, genetic, and developmental analysis. Mol Endocrinol. 2006; 20(11):2796–805. PMID: 16840539.

17. Ellsworth BS, Burns AT, Escudero KW, Duval NL, Nelson SE, Clay CM. The gonadotropin releasing hormone (GnRH) receptor activating sequence (GRAS) is a composite regulatory element that interacts with multiple classes of transcription factors including Smads, AP-1 and a forkhead DNA binding protein. Molecular and Cellular Endocrinology. 2003; 206:93–111. PMID: 12943993.

18. Cos S, Mellon PL, Thackray VG. A FoxL in the Smad house: activin regulation of FSH. Trends Endocrinol Metab. 2010; 21(9):568–77. Epub 2010/07/06. S1043-2760(10)00094-9 [pii] doi: 10.1016/j.tem.2010.05.006 PMID: 20598900.

19. Lamba P, Fortin J, Tran S, Wang Y, Bernard DJ. A novel role for the forkhead transcription factor FOXL2 in activin A-regulated follicle-stimulating hormone beta subunit transcription. Mol Endocrinol. 2009; 23(7):1001–13. Epub 2009/03/28. me.2008-0324 [pii] doi: 10.1210/me.2008-0324 PMID: 19324968.

20. Justice NJ, Blount AL, Pelosi E, Schlessinger D, Vale W, Bilezikjian LM. Impaired FSH(beta) Expression in the Pituitaries of Foxl2 Mutant Animals. Mol Endocrinol. 2011; 25(8):1404–15. Epub 2011/06/28. me.2011-0093 [pii] doi: 10.1210/me.2011-0093 PMID: 21700720.

21. Tran S, Zhou X, Laffler C, Calderon MJ, Ellsworth BS, Kimmins S, et al. Impaired fertility and FSH synthesis in gonadotrope-specific Foxl2 knockout mice. Mol Endocrinol. 2013; 27(3):407–21. Epub 2013/01/24. me.2012-1286 [pii] doi: 10.1210/me.2012-1286 PMID: 23340250.

22. Jung DO, Jasurda JS, Egashira N, Ellsworth BS. The Forkhead Transcription Factor, FOXP3, Is Required for Normal Pituitary Gonadotropin Expression in Mice. Biol Reprod. 2012; 86(5):144. Epub 2012/02/24. bioioprod.11.094904 [pii] doi: 10.1095/bioprod.11.094904 PMID: 22357547.

23. Godfrey VL, Wilkinson JE, Rinchik EM, Russell LB. Fatal lymphoreticular disease in the scurfy (sf) mouse requires T cells that mature in a sf thymic environment: potential model for thymic education. Proc Natl Acad Sci U S A. 1991; 88(13):5526–32. PMID: 2062835.

24. Lyon MF. Hypogonadism in scurfy (sf) males. Mouse News Letter. 1986; 74:93.

25. Gumbel JH, Patterson EM, Owusu SA, Kabat BE, Jung DO, Simmons J, et al. The forkhead transcription factor is essential for embryonic development of pulmonary vasculature. J Biol Chem. 2012; 287(35):30699–704. PMID: 22865884.

26. Norquay LD, Yang X, Jin Y, Dettlieux KA, Cattini PA. Hepatocyte nuclear factor-3alpha binding at P sequences of the human growth hormone locus is associated with pituitary repressor function. Mol Endocrinol. 2006; 20(23):22278–86. Epub 2005/04/09. M500936200 [pii] doi: 10.1210/jeb.200502156 PONE-D-12-12923 [pii] PMID: 12943993.

27. Arriola DJ, Mayo SL, Skarra DV, Benson CA, Thackray VG. FOXO1 inhibits transcription of luteinizing hormone beta in pituitary gonadotrope cells. J Biol Chem. 2012; 287:33424–5. Epub 2012/02/24. biolreprod.11.094904 [pii] doi: 10.1095/biolreprod.11.094904 PMID: 22357547.

28. Godfrey VL, Wilkinson JE, Rinchik EM, Russell LB. Fatal lymphoreticular disease in the scurfy (sf) mouse requires T cells that mature in a sf thymic environment: potential model for thymic education. Proc Natl Acad Sci U S A. 1991; 88(13):5526–32. PMID: 2062835.

29. Godfrey VL, Wilkinson JE, Rinchik EM, Russell LB. Fatal lymphoreticular disease in the scurfy (sf) mouse requires T cells that mature in a sf thymic environment: potential model for thymic education. Proc Natl Acad Sci U S A. 1991; 88(13):5526–32. PMID: 2062835.

30. Godfrey VL, Wilkinson JE, Rinchik EM, Russell LB. Fatal lymphoreticular disease in the scurfy (sf) mouse requires T cells that mature in a sf thymic environment: potential model for thymic education. Proc Natl Acad Sci U S A. 1991; 88(13):5526–32. PMID: 2062835.

31. Caminci P, Waki K, Shiraki T, Konno H, Shibata K, Itoh M, et al. Targeting a complex transcriptome: the construction of the mouse full-length cDNA encyclopedia. Genome Res. 2003; 13(6B):1273–89. PMID: 12819125.

32. Nowakowski RS, Lewin SB, Miller MW. Bromodeoxyuridine immunohistochemical determination of the lengths of the cell cycle and the DNA-synthetic phase for an anatomically defined population. J Neurocytol. 1988; 18(3):311–8. PMID: 2746304.
33. Prigent C, Dimitrov S. Phosphorylation of serine 10 in histone H3, what for? J Cell Sci. 2003; 116(Pt 18):3677–85. Epub 2003/08/15. doi:10.1242/jcs.00735116/18/3677 [pii]. PMID:12917355.

34. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001; 25(4):402–8. Epub 2002/02/16. doi:10.1006/ meth.2001.1262 S1046-2023(01)91262-9 [pii]. PMID:11846609.

35. Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc. 2008; 3(6):101–8. Epub 2008/06/13. PMID:18546601.

36. Zhu X, Gleiberman AS, Rosenfeld MG. Molecular pathways of pituitary development: signaling and transcriptional networks. Physiol Rev. 2007; 87(3):933–63. Epub 2007/07/07. 87/3/933 [pii] doi:10.1152/physrev.00006.2006 PMID:17615393.

37. Koo C-Y, Muir KW, Lam EW. FOXM1: from cancer initiation to progression and treatment. Biochim Biophys Acta. 2012; 1819:28–37. doi:10.1016/j.bbagrm.2011.09.004 PMID:21978825.

38. Bilodeau S, Roussel-Gervais A, Drouin J. Distinct Developmental Roles of Cell Cycle Inhibitors P57kip1 and P27kip2 Distinguish Pituitary Progenitor Cell Cycle Exit from Cell Cycle Re-Entry of Differentiated Cells. Mol Cell Biol. 2009. Epub 2009/01/14. MCB.01885-08 [pii] doi:10.1128/MCB.01885-08 PMID:19139274.

39. Calvisi DF, Pinna F, Ladu S, Pellegrino R, Simile MM, Frau M, et al. Forkhead box M1B is a determinant of rat susceptibility to hepatocarcinogenesis and sustains ERK activity in human HCC. Gut. 2009; 58(5):679–87. doi:10.1136/gut.2008.152652 PMID:19136513.

40. Zhang W, Liu HT. MAPK signal pathways in the regulation of cell proliferation in mammalian cells. Cell research. 2002; 12(1):9–18. Epub 2002/04/11. doi:10.1038/sj.cr.7290105 PMID:11942415.

41. Zhang N, Wei P, Gong A, Chi Wu, Lee HT, Colman H, et al. FoxM1 promotes beta-catenin nuclear localization and controls Wnt target-gene expression and glioma tumorigenesis. Cancer Cell. 2011; 20(4):427–42. doi:10.1016/j.ccr.2011.08.016 PMID:22014570; PubMed Central PMCID:PMC3199318.

42. Costa RH. FoxM1 dances with mitosis. Nat Cell Biol. 2005; 7(2):109–10. PMID:15689977.

43. Japon MA, Rubinstein M, Low MJ. In situ hybridization analysis of anterior pituitary hormone gene expression during fetal mouse development. J Histochem Cytochem. 1994; 42(8):1117–25. PMID:8027530.

44. Wierstra I. The transcription factor FOXM1 (Forkhead box M1): proliferation-specific expression, transcription factor function, target genes, mouse models, and normal biological roles. Advances in cancer research. 2013; 118:97–398. doi:10.1016/B978-0-12-407173-5.00004-2 PMID:23768511.

45. Salisbury TB, Binder AK, Nilson JH. Welcoming beta-catenin to the gonadotropin-releasing hormone transcriptional network in gonadotropes. Mol Endocrinol. 2008; 22(6):1295–303. doi:10.1210/me.2007-0515 PMID:18218726.

46. Waite E, Lafont C, Carmignac D, Chauvet N, Couty N, Christian H, et al. Different degrees of somatotroph ablation compromise pituitary growth hormone cell network structure and other pituitary endocrine cell types. Endocrinology. 2010; 151(1):234–43. doi:10.1210/en.2009-0539 PMID:19887571.